IMMXImmix Biopharma, Inc.
$9.30+271% 1Y
$9.30
$2.4852 weeks$14.59
Price
+271%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 3% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for IMMX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$662.1M
1 year+271%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026On September 29, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, pursuant to which the Company agreed to issue and sell, in an underwritten offering (the “Offering”), an aggregate of 11,363,637 …Other event · Form 8-K
- Sep 29, 2026On September 29, 2026, the Company announced an update from the Phase 2 NEXICART-2 clinical trial, including positive results of an 89% (40/45) complete response (“CR”) rate across all forty-five relapsed/refractory AL Amyloidosis patients enrolled in the trial, as assessed by an independent review committee.Regulation FD disclosure · Form 8-K
- Jul 20, 2026As of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.